Skip to content

News Releases

Filter Releases
 
News Releases
Date Title and Summary View
Feb 3, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/03/12 -- Threshold Pharmaceuticals, Inc (NASDAQ: THLD) Threshold to receive $25 million upfront, plus further potential milestones and royalties Deal provides Threshold option to co-commercialize in the United States Phase 3 trial in soft tissue sarcoma on-going and randomi...
Feb 17, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/17/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Tillman Pearce, M.D. as its Chief Medical Officer. In this position, Dr. Pearce will oversee the development of Threshold's TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evalua...
Feb 21, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/21/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Primary endpoint of Progression Free Survival was met with hazard ratio of 0.61 (p = 0.005). The combination therapy was well tolerated with a safety profile consistent with prior studies. Threshold Pharmaceu...
Feb 24, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 02/24/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the 32nd Annual Cowen Health Care Conference in Boston on Tuesday, March 6, 2012 at 10:00AM EST. A live webcast of the prese...
Mar 6, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/06/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held on March 31st - April 4th 2012, in Chicago, IL. The presentation will ...
Mar 8, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/08/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter and year ended December 31, 2011 was $5.3 million and $25.7 million, respectively. As of December 31, 2011, Thresho...
Mar 12, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/12/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry experts at a symposium entitled Therapeutic and Diagnostic Modalities Targeting Hypoxia in Cancer, hosted by the New York Academy of Sciences on Wedne...
Mar 14, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/14/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the first patient has been dosed in its Phase 1/2 clinical trial of TH-302 as monotherapy and in combination with bortezomib in patients with relapsed/refractory multiple myeloma who have received at least two prior lines...
Mar 16, 2012
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 03/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma. "Receiving orphan designation for TH-302 in soft tissue sarcoma in the E...
Mar 28, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/28/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that TH-302 will be featured in four presentations, including a late-breaking clinical trial session, at the American Association for Cancer Research (AACR) Annual Meeting, to be held on March 31 - April 4, 2012, in Chicago, IL...
Mar 30, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma. "Following our announcement on March 16 regarding the r...
Mar 30, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) Primary progression-free survival efficacy endpoint met (p=0.005) Response rate of 27% and median PFS of 6.0 months in highest TH-302 dose group Dose-dependent TH-302-related toxicity did not increase discontinuations du...
Apr 11, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/11/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany, for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled Phase 2 clinical trial ("40...
Apr 13, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present at the 19th Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, April 20, at 10:30 a.m. Eastern time in New York Ci...
Apr 25, 2012
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Robert Simon as Senior Vice President of Regulatory Affairs. Mr. Simon will oversee Threshold's regulatory activities related to the development of TH-302, a clinical stage hypoxia-targeted cancer therapeutic...
Page:
...
Next Last